Literature DB >> 3652098

On the possible role of long chain fatty acylcarnitine accumulation in producing functional and calcium permeability changes in membranes during myocardial ischaemia.

J M Lamers1, J T De Jonge-Stinis, P D Verdouw, W C Hülsmann.   

Abstract

A radioisotope procedure was used to determine long chain fatty acylcarnitine concentrations in fractions of porcine myocardium that had been subjected to different periods of ischaemia (0, 1, 2, and 3 h). In myocardial tissue from non-ligated hearts acylcarnitine concentrations were 0.32(0.03) and 1.53(0.04) nmol.mg-1 protein for homogenate and sarcolemma enriched membrane respectively, which indicates a preferential membrane localisation of long chain fatty acylcarnitine. Both the total and membrane acylcarnitine contents were increased about twofold after 2 h of ischaemia. The accumulation of long chain fatty acylcarnitine was not correlated temporally with changes in adenosine triphosphate dependent calcium uptake activity of homogenates (mainly a function of sarcoplasmic reticulum membranes), sodium gradient induced calcium uptake, and calcium permeability of sarcolemma preparations. Homogenate adenosine triphosphate dependent calcium uptake was decreased by 36% after 3 h of ischaemia. Sodium gradient induced calcium uptake was enhanced about twofold after 1 h of ischaemia, and calcium permeability of sarcolemmal vesicles was decreased by 20% after 3 h of ischaemia. After in vitro incubation of isolated sarcolemma membranes with (1-14C)-palmitoylcarnitine radiolabelled molecules that remained associated with the membrane even after repeated washing were incorporated. No changes were observed in the sodium gradient induced calcium uptake when less than 6 nmol (1(-14)C)- palmitoylcarnitine per mg sarcolemma protein were bound or incorporated into the lipid phase. This exceeded the maximal endogenous concentrations of 3.2(0.6) nmol long chain fatty acylcarnitine per mg sarcolemma protein observed during myocardial ischaemia. The results suggest that the intracellular increase in long chain acylcarnitine during almost zero myocardial flow is not critical to sarcolemmal sodium and calcium permeability and sarcoplasmic reticulum calcium pumping activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3652098     DOI: 10.1093/cvr/21.5.313

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  7 in total

Review 1.  Free fatty acid metabolism during myocardial ischemia and reperfusion.

Authors:  S C Hendrickson; J D St Louis; J E Lowe; S Abdel-aleem
Journal:  Mol Cell Biochem       Date:  1997-01       Impact factor: 3.396

Review 2.  Intracellular transport of lipids.

Authors:  J F Glatz; G J van der Vusse
Journal:  Mol Cell Biochem       Date:  1989 Jun 27-Jul 24       Impact factor: 3.396

3.  The myocardial distribution and plasma concentration of carnitine in patients with mitral valve disease.

Authors:  T Nakagawa; M Sunamori; A Suzuki
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

Review 4.  Significance of cytoplasmic fatty acid-binding protein for the ischemic heart.

Authors:  J F Glatz; M M Vork; G J van der Vusse
Journal:  Mol Cell Biochem       Date:  1993 Jun 9-23       Impact factor: 3.396

5.  Effects of palmitoyl carnitine and related metabolites on the avian Ca(2+)-ATPase and Ca2+ release channel.

Authors:  E Dumonteil; H Barré; G Meissner
Journal:  J Physiol       Date:  1994-08-15       Impact factor: 5.182

6.  L-propionylcarnitine and myocardial performance in stunned porcine myocardium.

Authors:  L M Sassen; D J Duncker; A Hogendoorn; E O McFalls; R Krams; K Bezstarosti; J M Lamers; P D Verdouw
Journal:  Mol Cell Biochem       Date:  1992-10-21       Impact factor: 3.396

7.  Effects of L-propionylcarnitine on electrical and mechanical alterations induced by amphiphilic lipids in isolated guinea pig ventricular muscle.

Authors:  M Aomine; M Arita; T Shimada
Journal:  Heart Vessels       Date:  1988       Impact factor: 2.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.